CN100349885C - 依他普仑氢溴酸盐及其制备方法 - Google Patents

依他普仑氢溴酸盐及其制备方法 Download PDF

Info

Publication number
CN100349885C
CN100349885C CNB2003801063775A CN200380106377A CN100349885C CN 100349885 C CN100349885 C CN 100349885C CN B2003801063775 A CNB2003801063775 A CN B2003801063775A CN 200380106377 A CN200380106377 A CN 200380106377A CN 100349885 C CN100349885 C CN 100349885C
Authority
CN
China
Prior art keywords
disorder
escitalopram
escitalopram hydrobromide
treatment
hydrobromide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB2003801063775A
Other languages
English (en)
Chinese (zh)
Other versions
CN1726202A (zh
Inventor
L·马特尔
R·丹塞尔
H·彼得森
P·埃勒加德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
H Lundbeck AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32668635&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN100349885(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H Lundbeck AS filed Critical H Lundbeck AS
Publication of CN1726202A publication Critical patent/CN1726202A/zh
Application granted granted Critical
Publication of CN100349885C publication Critical patent/CN100349885C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CNB2003801063775A 2002-12-23 2003-12-18 依他普仑氢溴酸盐及其制备方法 Expired - Fee Related CN100349885C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200202005 2002-12-23
DKPA200202005 2002-12-23

Publications (2)

Publication Number Publication Date
CN1726202A CN1726202A (zh) 2006-01-25
CN100349885C true CN100349885C (zh) 2007-11-21

Family

ID=32668635

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2003801063775A Expired - Fee Related CN100349885C (zh) 2002-12-23 2003-12-18 依他普仑氢溴酸盐及其制备方法

Country Status (32)

Country Link
US (1) US20040167209A1 (https=)
EP (1) EP1578738B1 (https=)
JP (2) JP4658613B2 (https=)
KR (1) KR20050086933A (https=)
CN (1) CN100349885C (https=)
AR (1) AR042652A1 (https=)
AT (1) ATE388947T1 (https=)
AU (1) AU2003287919B2 (https=)
BR (1) BR0317623A (https=)
CA (1) CA2511142A1 (https=)
CY (1) CY1107451T1 (https=)
DE (1) DE60319739T2 (https=)
DK (1) DK1578738T3 (https=)
EA (1) EA013116B1 (https=)
EG (1) EG24729A (https=)
ES (1) ES2298595T3 (https=)
IL (1) IL169125A0 (https=)
IS (1) IS2654B (https=)
ME (1) MEP5808A (https=)
MX (1) MXPA05005772A (https=)
MY (1) MY135468A (https=)
NO (1) NO20053595L (https=)
NZ (1) NZ540281A (https=)
PE (1) PE20040924A1 (https=)
PL (1) PL378275A1 (https=)
PT (1) PT1578738E (https=)
RS (1) RS51092B (https=)
TW (1) TW200501943A (https=)
UA (1) UA80170C2 (https=)
UY (1) UY28148A1 (https=)
WO (1) WO2004056791A1 (https=)
ZA (1) ZA200504109B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA80170C2 (en) * 2002-12-23 2007-08-27 Lundbeck & Co As H Escitalopram hydrobromide
US20050137255A1 (en) * 2002-12-23 2005-06-23 H. Lundbeck A/S Crystalline escitalopram hydrobromide and methods for preparing the same
AU2005218713B2 (en) * 2004-03-05 2009-11-19 H. Lundbeck A/S Crystalline composition containing escitalopram oxalate
TWI358407B (en) 2005-06-22 2012-02-21 Lundbeck & Co As H Crystalline base of escitalopram and orodispersibl
US7834201B2 (en) 2005-06-22 2010-11-16 H. Lundbeck A/S Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base
AU2006304889A1 (en) * 2005-10-14 2007-04-26 H. Lundbeck A/S Stable pharmaceutical formulations containing escitalopram and bupropion
EP1954257A4 (en) * 2005-10-14 2009-05-20 Lundbeck & Co As H METHOD FOR TREATING DISORDERS OF THE CENTRAL NERVOUS SYSTEM WITH A LOW-DOSED COMBINATION OF ESCITALOPRAM AND BUPROPION
TW200812993A (en) * 2006-05-02 2008-03-16 Lundbeck & Co As H New uses of escitalopram
ES2687756T3 (es) * 2006-07-11 2018-10-29 Mitsubishi Tanabe Pharma Corporation Sal de un compuesto de morfolina
WO2008059514A2 (en) * 2006-07-31 2008-05-22 Cadila Healthcare Limited Process for preparing escitalopram
FR3006594A1 (fr) * 2013-06-11 2014-12-12 Sorin Crm Sas Microsonde implantable de detection/stimulation incorporant un agent anti-inflammatoire
CN108976188B (zh) * 2017-06-05 2022-12-06 上海奥博生物医药股份有限公司 一种艾司西酞普兰双羟萘酸盐新的制备方法
RU2020111694A (ru) * 2017-10-09 2021-11-12 Тева Фармасьютикал Индастриз Лтд. Новые соли и твердые формы эсциталопрама
US20240100012A1 (en) 2021-01-18 2024-03-28 Mark Hasleton Pharmaceutical dosage form

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0347066A1 (en) * 1988-06-14 1989-12-20 H. Lundbeck A/S New enantiomers and their isolation
EP1152000A1 (en) * 2000-05-02 2001-11-07 SUMIKA FINE CHEMICALS Co., Ltd. Citalopram hydrobromide crystal and method for crystallization thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US34712A (en) * 1862-03-18 James h
GB1526331A (en) * 1976-01-14 1978-09-27 Kefalas As Phthalanes
GB8419963D0 (en) * 1984-08-06 1984-09-12 Lundbeck & Co As H Intermediate compound and method
CA2291134C (en) * 1998-10-20 2006-05-23 H. Lundbeck A/S Method for the preparation of citalopram
AR021155A1 (es) * 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
TR200401456T1 (tr) * 1999-10-25 2005-04-21 H. Lundbeck A/S Sitalopram hazırlanması için yöntem.
JP2002020379A (ja) * 2000-05-02 2002-01-23 Sumika Fine Chemicals Co Ltd シタロプラム臭化水素酸塩の結晶およびその結晶化方法
IES20010693A2 (en) * 2000-08-10 2002-07-10 Lundbeck & Co As H Pharmaceutical composition containing citalopram
BR0115907B1 (pt) * 2000-12-04 2011-10-04 processo para o tratamento prévio de óleos crus e graxas cruas para uma subsequente transesterificação alcalina com álcoois primários e/ou secundários e processo para a produção de ésteres de ácido graxo de álcoois primários e/ou secundários a partir de óleos crus ou graxas cruas que contém ácidos graxos livres e substáncias mucilaginosas ou a partir de óleos velhos carregados com ácidos graxos livres da indústria alimentìcia.
EA200301195A1 (ru) * 2001-05-01 2004-04-29 Х. Лундбекк А/С Применение энантиомерно чистого эсциталопрама
AR034612A1 (es) * 2001-06-25 2004-03-03 Lundbeck & Co As H Proceso para la preparacion del citalopram racemico y/o del s- o r-citalopram mediante la separacion de una mezcla de r- y s-citalopram
UA80170C2 (en) * 2002-12-23 2007-08-27 Lundbeck & Co As H Escitalopram hydrobromide
US20050174782A1 (en) * 2003-03-25 2005-08-11 Chapman Leonard T. Flashlight

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0347066A1 (en) * 1988-06-14 1989-12-20 H. Lundbeck A/S New enantiomers and their isolation
EP1152000A1 (en) * 2000-05-02 2001-11-07 SUMIKA FINE CHEMICALS Co., Ltd. Citalopram hydrobromide crystal and method for crystallization thereof

Also Published As

Publication number Publication date
CA2511142A1 (en) 2004-07-08
EA200501046A1 (ru) 2005-12-29
US20040167209A1 (en) 2004-08-26
DE60319739T2 (de) 2008-07-17
TW200501943A (en) 2005-01-16
JP2011037893A (ja) 2011-02-24
MEP5808A (xx) 2010-02-10
NZ540281A (en) 2008-07-31
JP2006514952A (ja) 2006-05-18
CY1107451T1 (el) 2012-12-19
DE60319739D1 (de) 2008-04-24
PL378275A1 (pl) 2006-03-20
DK1578738T3 (da) 2008-06-30
IL169125A0 (en) 2009-02-11
MY135468A (en) 2008-04-30
PT1578738E (pt) 2008-04-11
RS20050487A (sr) 2007-06-04
EA013116B1 (ru) 2010-02-26
EP1578738A1 (en) 2005-09-28
HK1087708A1 (en) 2006-10-20
PE20040924A1 (es) 2004-12-11
RS51092B (sr) 2010-10-31
IS2654B (is) 2010-08-15
BR0317623A (pt) 2005-11-29
AU2003287919B2 (en) 2009-11-12
EG24729A (en) 2010-06-21
KR20050086933A (ko) 2005-08-30
ZA200504109B (en) 2006-08-30
CN1726202A (zh) 2006-01-25
WO2004056791A1 (en) 2004-07-08
EP1578738B1 (en) 2008-03-12
JP4658613B2 (ja) 2011-03-23
AR042652A1 (es) 2005-06-29
MXPA05005772A (es) 2005-08-16
ATE388947T1 (de) 2008-03-15
NO20053595L (no) 2005-09-05
UY28148A1 (es) 2004-09-30
ES2298595T3 (es) 2008-05-16
UA80170C2 (en) 2007-08-27
IS7848A (is) 2005-05-17
AU2003287919A1 (en) 2004-07-14

Similar Documents

Publication Publication Date Title
CN100349885C (zh) 依他普仑氢溴酸盐及其制备方法
JPH11505229A (ja) ４−アリール−ピペリジン誘導体を製造する方法
SK512004A3 (en) Process for the preparation of racemic citalopram and/or S- or R-citalopram by separation of a mixture of R- and S-citalopram
US8288568B2 (en) Process for the preparation of escitalopram
EP1137646A1 (en) Derivative of paroxetine
HK1087708B (en) Escitalopram hydrobromide and a method for the preparation thereof
JPH09500139A (ja) ヒドロキシルアミンの酸付加塩の合成法
TWI225055B (en) Process for the preparation of 5-substituted isobenzofurans
EP0649419A1 (fr) Derives de la n-cycloalkylpiperazine, procedes d'obtention et compositions pharmaceutiques les contenant
CN1213991C (zh) 偏亚环己基胺顺式选择性催化加氢工艺
CN1516585A (zh) 限制粉红色化合物生成的帕罗西汀盐酸盐的制备方法
US7566793B2 (en) Process for resolving citalopram
EP1135382A1 (en) Method of producing paroxetine hydrochloride
EP1042318A1 (en) Process for the preparation of paroxetine hydrochloride
JP2006512278A (ja) アルコキシ不純物を実質的に含有しないパロキセチンの製造方法
WO2007054978A2 (en) Process for preparing paroxetine hydrochloride hemihydrate
WO2014049609A2 (en) Novel salts of vilazodone
CN1300286A (zh) 帕罗西丁的晶形
CN1204319A (zh) 制备1－苄基－4－(5,6－二甲氧基－1－二氢化茚酮)－2－基)甲基哌啶的方法和中间体
WO2000039090A1 (en) Process for the preparation of paroxetine acetate and analogues thereof
WO2000039123A1 (en) Process for the preparation of an acetate salt of paroxetine or paroxetine analogues
JP2017019727A (ja) デュロキセチン塩基及びデュロキセチン塩酸塩の製造方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1087708

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1087708

Country of ref document: HK

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20071121

Termination date: 20101218